Ahmed A. Suleiman - Concepedia

Author

Ahmed A. Suleiman

Also Known As

A A Suleiman, A Suleiman, A. A. Suleiman, A. Suleiman, Ahmed A Suleiman, Ahmed A. Suleiman, Ahmed Abbas Suleiman, Ahmed Jassim Suleiman, Ahmed Suleiman, Ahmed Suleiman Jr

Publications

730

Citations

H-Index

Concepts

All Affiliations

AbbVie (United States)AbbVie (Germany)University Hospital Cologne Pfizer (United States)Centre for Human Drug Research

About

Ahmed A. Suleiman is an author at AbbVie (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	349
2	Engineering	2	2	25
3	Health Sciences	2	2	139
4	Natural Sciences	1	1	12
5	Social Sciences	1	1	31

Ahmed A. Suleiman

Publications

555

Citations

H-Index

Page 1

	Year	Citations
Adding external beam to intra-luminal brachytherapy improves palliation in obstructive squamous cell oesophageal cancer: A prospective multi-centre randomized trial of the International Atomic Energy Agency Eduardo Rosenblatt, Glenn Jones, Ranjan Sur, Radiotherapy and Oncology Esophageal CancerRadiation TherapyMedicineIntra-luminal BrachytherapyBrachytherapy	2010	102
A Semiphysiological Population Pharmacokinetic Model for Dynamic Inhibition of Liver and Gut Wall Cytochrome P450 3A by Voriconazole Sebastian Frechen, Lisa Junge, Teijo I. Saari, Clinical Pharmacokinetics Pharmacokinetic ModelingBiochemistryPharmacodynamicsMedicineHealth Sciences	2013	37
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn’s Disease: A Post Hoc Analysis From the CALM Study Walter Reinisch, Remo Panaccione, Peter Bossuyt, Inflammatory Bowel Diseases Abstract Background CalmFecal CalprotectinCalm StudyGastrointestinal PharmacologyClinical Endpoint	2020	37
Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials Ahmed A. Suleiman, Mukul Minocha, Amit Khatri, Clinical Pharmacokinetics	2019	35
Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials Ahmed A. Suleiman, Amit Khatri, Mukul Minocha, Clinical Pharmacokinetics	2018	32
Modelling and Simulation of the Positive and Negative Syndrome Scale (PANSS) Time Course and Dropout Hazard in Placebo Arms of Schizophrenia Clinical Trials Venkatesh Pilla Reddy, Magdalena Kozielska, Martin Johnson, Clinical Pharmacokinetics NeuropsychologyPsychopathologyDropout HazardPsychiatryRisk Prediction	2012	31
Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis Amit Khatri, Doerthe Eckert, Rajneet K. Oberoi, The Journal of Clinical Pharmacology White Healthy SubjectsTranslational MedicineAutoimmune DiseaseGeneralized Pustular PsoriasisRisankizumab Exposures	2019	29
Pharmacokinetic–pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: The use of PANSS total score and clinical utility Venkatesh Pilla Reddy, Magdalena Kozielska, Ahmed A. Suleiman, Schizophrenia Research	2013	28
Population pharmacokinetic analysis of circadian rhythms in hepatic CYP3A activity using midazolam Dorota Tomalik‐Scharte, Ahmed A. Suleiman, Sebastian Frechen, The Journal of Clinical Pharmacology Drug DispositionPopulation Pharmacokinetic AnalysisPharmacotherapyExperimental PharmacologyPhysiologically-based Pharmacokinetic Modeling	2014	25
Exposure–Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis Ahmed A. Suleiman, Amit Khatri, Rajneet K. Oberoi, Clinical Pharmacokinetics MedicineExposure–response RelationshipsPharmacologyClinical DermatologyDermatology	2019	20

Page 1